𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

✍ Scribed by Dr J. Robert; F. Rigal-Huguet; P. Hurteloup

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
365 KB
Volume
10
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We have studied the pharmacokinetics of idarubicin and daunorubicin in a total of 16 leukemic patients treated with one of these drugs associated with aracytine. The AUCs obtained for unchanged drugs were proportional to the dose, and the dose‐independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39·0L/h/m^2^ for idarubicin versus 38·6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m^2^) and elimination half‐life (42·7 versus 47·4 h). The only metabolites detected were the 13–dihydroderivative of each drug, idarubicinol or daunorubicinol. The elimination half‐life of idarubicinol was two times higher than that of daunorubicinol (80·7 versus 37·3 h) which provided an AUC ratio metabolite/parent drug higher for idarubicin than for daunorubicin. In view of the fact that idarubicinol is a much more active metabolite than daunorubicinol, this protracted half‐life metabolite can account for the reported higher activity of idarubicin as compared to daunorubicin.

📜 SIMILAR VOLUMES

Kinetics and sensitivity of daunorubicin
Kinetics and sensitivity of daunorubicin in patients with acute leukemia
✍ Michael W. DeGregorio; Walter M. Holleran; Bruce A. Macher; Charles A. Linker; J 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 512 KB

Leukemia cells isolated from eight patients with acute leukemia before treatment were examined for in vitro uptake of daunorubicin (DNR) and inhibition of DNA synthesis. In addition, plasma and cellular levels of DNR and daunorubicinol (DOL) were examined in six of the eight patients. Inhibition of

A comparative pharmacokinetic study of i
A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy
✍ D.M. Bell; G. Richards; S. Dhillon; J.R. Oxley; J. Cromarty; J.W.A.S. Sander; P. 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 605 KB

The pharmacokinetics of midazolam, a water soluble 1,4-benzodiazepine, has been studied in 12 patients (11 male, 1 female; age range 19-57 years) with epilepsy. All patients were taking hepatic enzyme inducing antiepileptic drugs (AEDs) on a regular basis. Midazolam (5 mg) was administered intraveno

Comparative uptake of adriamycin and dau
Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry
✍ H. Tapiero; A. Fourcade; P. Vaigot; J. J. Farhi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB

## Abstract Based on the fluorescence properties of adriamycin (ADM) and daunorubicin (DNR), uptake in sensitive and resistant Friend leukemia cells (FLC) was studied with the aid of the fluorescence activated cell sorter (FACS II). A quantitative cell by cell fluorescence intensity analysis showed